Browsing Tag

iBio

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

<!--…
Read More...

NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of…
Read More...

Data Showing Greater Glycosylation Homogeneity with the FastPharming® System Compared to Traditional Methods to be…
Read More...

BRYAN, Texas, Jan. 04, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of…
Read More...

BRYAN, Texas, Oct. 26, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of…
Read More...

BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of…
Read More...

BRYAN, Texas, July 08, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech…
Read More...